Danish drugmaker Novo Nordisk (NVO) (OTCPK:NONOF) and AI-focused biotech Valo Health announced Wednesday an agreement to ...

Under the expanded collaboration, Valo's Opal Computational Platform will be integrated with Novo Nordisk's expertise in cardiometabolic diseases, deriving insights from real-world patient data, ...

Fintel reports that on January 5, 2025, BNP PARIBAS EXANE upgraded their outlook for Novo Nordisk A (NYSE:NVO) from Neutral ...

Kuykendall has been in his current role since July 2022. Interesting fact: He has worked with Novo Nordisk for more than 18 ...

Pharmaceutical stalwart Novo Nordisk (NVO) can’t seem to get anything good going these days. As TipRanks’ Vince Condarcuri ...

Novo Nordisk A/S (NYSE:NVO – Get Free Report) was upgraded by equities researchers at Sanford C. Bernstein from an “underperform” rating to a “market perform” rating in a research note issued on ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

Investors in Novo-Nordisk AS (Symbol: NVO) saw new options begin trading today, for the February 2025 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVO ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...